Kaiser Foundation Health Plan, Inc.

Kaiser Foundation Health Plan, Inc. is a non-profit health plan that operates as part of the Kaiser Permanente integrated healthcare system, serving over 12 million members across 8 states and Washington D.C. Through its unique model that combines health insurance with healthcare delivery, Kaiser Permanente aims to provide high-quality, affordable healthcare services and improve health outcomes. Kaiser Foundation Health Plan, Inc. and its subsidiaries have received numerous federal contract and grant awards to provide a wide range of healthcare-related services and conduct medical research. These include vaccine safety surveillance, clinical trials, epidemiological studies, and implementation of evidence-based health interventions.

Through federal contracts, Kaiser Foundation Health Plan, Inc. has primarily supported public health agencies like the Centers for Disease Control and Prevention (CDC) and Department of Veterans Affairs (VA). Notable contract work includes conducting vaccine safety surveillance through the CDC's Vaccine Safety Datalink program, evaluating the effectiveness of COVID-19 and influenza vaccines, and supporting clinical immunization safety assessments. Kaiser has also provided research and development survey services for VA medical centers and operated vaccine treatment and evaluation units for the National Institutes of Health (NIH). Most of these contract awards have been issued as prime contracts without set-aside designations, reflecting Kaiser's status as a large, established healthcare organization. As a subcontractor, Kaiser has supported emergency protective health measures in response to the COVID-19 pandemic for state agencies.

Kaiser Foundation Health Plan, Inc. and its subsidiaries have received numerous federal grant awards, both as prime recipients and subrecipients, to conduct medical research and implement health interventions. As a prime grantee, Kaiser has received awards from the CDC to evaluate influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness. As a subrecipient, Kaiser has participated in a wide variety of research initiatives funded by NIH institutes and other health agencies. These include studies on gestational diabetes risk, dementia and cognitive decline, blood pressure control in diverse populations, cancer screening and treatment, mental health interventions, and health disparities. Kaiser frequently collaborates with academic institutions and other healthcare systems on these grants, leveraging its large patient population and comprehensive electronic health records to support clinical and population health research.

Kaiser Foundation Health Plan, Inc. holds several significant indefinite delivery vehicles (IDVs) that enable ongoing federal research initiatives. A major IDV is the Clinical Immunization Safety Assessment (CISA) program, awarded by the CDC, with a potential value of $86 million. This contract facilitates epidemiological and clinical research to evaluate vaccine safety through collaboration with integrated healthcare delivery organizations. Another important IDV is the Vaccine Safety Datalink program, valued at $149 million, which supports ongoing vaccine safety monitoring and rapid detection of potential risks. Kaiser also holds an IDV for the Coronary Artery Risk Development in Young Adults (CARDIA) study with the National Heart, Lung, and Blood Institute, to investigate cardiovascular disease risk factors from early adulthood through middle age. Additionally, Kaiser has a Blanket Purchase Agreement with the Department of the Army Medical Command to provide ancillary healthcare services in Hawaii. These IDVs demonstrate Kaiser's long-term commitment to supporting federal public health research initiatives.